Overcoming developability challenges when designing next-gen bi/multi-specifics
03 Nov 2026
Bi/Multispecifics
- How can molecular architecture be optimised to balance potency, stability and manufacturability?
- What strategies can reduce aggregation, chain mispairing and unwanted molecular interactions?
- How can expression yields and purification efficiency be improved for complex bispecific and immunocytokine formats?
- How can cytokine activity be controlled to maintain tumour targeting while minimising systemic toxicity?
- Which analytical approaches are most effective for characterisation, comparability and scale-up?